D-1441-2019 Class II Terminated

Recalled by Zydus Pharmaceuticals USA Inc — Pennington, NJ

FDA drug recall D-1441-2019 was initiated by Zydus Pharmaceuticals USA Inc on May 6, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure. The recall status is terminated (terminated Sep 16, 2021). Affected quantity: 768 1000-count bottles.

Recall details

Product Type
Drugs
Report Date
Jun 26, 2019
Initiation Date
May 6, 2019
Termination Date
Sep 16, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
768 1000-count bottles

Product description

Anastrozole Tablets, USP, 1 mg, 1,000-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534. NDC 68382-209-10

Reason for recall

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

Distribution pattern

Nationwide in the USA

Code information

Lot EXP Date: M708570 Jun-19, M711270 Sep-19, M802207 Feb-20, M812460 Aug-20

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1441-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1441-2019. Report a data issue: hello@regdatalab.com.